DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Rapid Sequence Intubation With Rocuronium-Sugammadex Compared With Succinylcholine

Information source: Rigshospitalet, Denmark
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rapid Sequence Intubation

Intervention: Rocuronium-Sugammadex (Drug); Succinylcholine (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Rigshospitalet, Denmark

Official(s) and/or principal investigator(s):
Martin K Sørensen, MD, Principal Investigator, Affiliation: Rigshospitalet, Denmark


Rapid sequence intubation is used, when there is an elevated risk of aspiration to the lungs of stomach content. It is typically used in acute settings that require acute surgery or in prehospital settings, but also in specific risk patients requiring elective surgery. The reason for conducting rapid sequence intubation is to minimize the risk of pulmonary aspiration and at the same time achieve a fast induction of anaesthesia and intubation. Rapid sequence intubation is a procedure with a high risk of complications in itself. The time period from induction of anaesthesia to intubation is particularly risky, because the patient is apneic. This study addresses this problem by investigating, how quickly spontaneous respiration can be reestablished after a rapid sequence intubation when using Rocuronium-Sugammadex compared to Succinylcholine. This is a pilot protocol that is intended to establish a sample size for the full protocol. Study hypothesis: The time from correct tube placement to spontaneous respiration is shorter when using Rocuronium/Sugammadex compared to Succinylcholine.

Clinical Details

Official title: Rapid Sequence Intubation With Rocuronium-Sugammadex Compared With Succinylcholine

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Time from verified correct tube placement after intubation to spontaneous respiration, defined as respiration frequency of >8/minute, tidal volume >3ml/kg and a saturation of >90% for 30 seconds.

Secondary outcome:

Duration of action. Measured as the time from administration of the neuromuscular blocking agent to the T1-value in Train-of-Four (TOF) returns to >90% of T1-max.

Intubation Difficulty Scale (IDS)

Intubation conditions

Side effect - Muscle ache.

Side effect - Tachycardia (>100 beats per minute).

Side effect - Bradycardia (<50 beats per minute).

Side effect - Awareness/recall. Evaluated by modified Brice Questionaire.


Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Both.


Inclusion Criteria:

- Elective surgical patients with a planned rapid sequence induction of anaesthesia.

- Informed consent.

- Legally competent.

- Be able to understand Danish and be able to read the given information in Danish.

- Females can only participate if they have reached menopause, have had hysterectomy

performed, use a coil as birthcontrol, or if they are sterilized. Exclusion Criteria:

- Presence of kidney disease, defined as S-creatinine >0,200 mmol/L.

- Known lung or heart disease, defined as NYHA-class >2 or CCS-class >2.

- Known allergic reactions to Rocuronium, Suxamethon, Propofol or Sugammadex.

- Contraindications to Suxamethon. Including raised P-potassium (>5,0 mmol/L),

untreated glaucoma, neuromuscular disorders or disposition to malignant hyperthermia.

- Body mass index of >35 kg/m2.

- Pregnant.

- Breastfeeding.

Locations and Contacts

Rigshospitalet, Copenhagen 2100, Denmark

Herlev Hospital, Herlev 2730, Denmark

Additional Information

Starting date: September 2009
Last updated: March 1, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017